ARS Pharmaceuticals Inc (SPRY) surge 10.11% in a week: will this be a lucky break through?

Shaun Noe

As on Wednesday, ARS Pharmaceuticals Inc (NASDAQ: SPRY) got off with the flyer as it spiked 7.55% to $11.11, before settling in for the price of $10.33 at the close. Taking a more long-term approach, SPRY posted a 52-week range of $9.34-$18.90.

Nevertheless, stock’s Earnings Per Share (EPS) this year is -2100.00%. This publicly-traded company’s shares outstanding now amounts to $98.70 million, simultaneously with a float of $58.37 million. The organization now has a market capitalization sitting at $1.10 billion. At the time of writing, stock’s 50-day Moving Average stood at $12.58, while the 200-day Moving Average is $13.43.

ARS Pharmaceuticals Inc (SPRY) Ownership Facts and Figures

Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. ARS Pharmaceuticals Inc’s current insider ownership accounts for 40.94%, in contrast to 62.77% institutional ownership. According to the most recent insider trade that took place on Aug 21 ’25, this organization’s PRESIDENT AND CEO sold 50,000 shares at the rate of 14.49, making the entire transaction reach 724,345 in total value, affecting insider ownership by 1,196,494. Preceding that transaction, on Aug 21 ’25, Company’s Chief Financial Officer sold 12,500 for 15.00, making the whole transaction’s value amount to 187,500. This particular insider is now the holder of 10,042 in total.

ARS Pharmaceuticals Inc (SPRY) Earnings and Revenue Records

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.

ARS Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -2100.00% and is forecasted to reach -0.76 in the upcoming year.

ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators

Let’s observe the current performance indicators for ARS Pharmaceuticals Inc (SPRY). It’s Quick Ratio in the last reported quarter now stands at 5.98. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 9.77.

In the same vein, SPRY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.49, a figure that is expected to reach -0.46 in the next quarter, and analysts are predicting that it will be -0.76 at the market close of one year from today.

Technical Analysis of ARS Pharmaceuticals Inc (SPRY)

Through scrutinizing the latest numbers posted by the [ARS Pharmaceuticals Inc, SPRY], it can be observed that its last 5-days Average volume of 2.53 million was better the volume of 1.83 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 71.29% While, its Average True Range was 69.44.

Raw Stochastic average of ARS Pharmaceuticals Inc (SPRY) in the period of the previous 100 days is set at 18.56%, which indicates a major fall in contrast to 100.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.61 that was lower than 0.78 volatility it exhibited in the past 100-days period.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.